This page shows the latest Novavax news and features for those working in and with pharma, biotech and healthcare.
Novavax has announced the initiation of a phase 2 trial for its combination COVID-19/influenza and stand-alone influenza vaccine candidates. ... Stanley Erck, president and chief executive officer, Novavax, said: "We're encouraged by the initiation of
Novavax’s protein-based vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant to enhance immune response and stimulate high levels of neutralising antibodies. ... A number of countries also have policy recommendations allowing use of the
Novavax has announced topline results from a phase 3 trial of its COVID-19 vaccines, showing that its Omicron-adapted BA.1 vaccine candidate, NVX-CoV2515, met the primary strain-change ... Additionally, the study showed no benefit for the Novavax
Novavax’s COVID-19 vaccine, Adjuvanted (NVX-CoV2373) has been granted emergency use authorisation (EUA) by the US Food and Drug Administration (FDA) as a booster in adults 18 years and ... strain. Stanley Erck, president and chief executive officer,
Novavax’s protein-based vaccine contains the SARS-CoV-2 spike protein and Matrix-M adjuvant to enhance immune response and stimulate high levels of neutralising antibodies. ... In the Novavax-sponsored trials, following the booster, local and systemic
Novavax’s COVID-19 vaccine – Nuvaxovid – has been recommended for expanded conditional marketing authorisation (CMA) by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for ... In the Novavax-sponsored
More from news
Approximately 26 fully matching, plus 37 partially matching documents found.
The CEPI has currently initiated eight COVID-19 vaccine developments with Curevac, Inovio Pharmaceuticals, Moderna, Novavax, The University of Hong Kong, The University of Oxford, The University of Queensland and a
30. Isconova / Novavax. Acquisition. Proprietary vaccine adjuvant technology. 30. Unless noted, transactions are for global rights.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Johnston joined Mucosis last May as chief business officer from the clinical biopharmaceutical company Novavax, where he served as vice president of strategy.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...